Thus, ADO accumulates in the TME predominantly through the catabolism of extracellular ATP to ADO by CD73, CD39, and CD38 expressed on tumor and immune cells, and has been reported to mediate suppression of anti-tumor immunity through activation of ADO receptors (Figure 1). The gene discussed is ENTPD1; the disease is neoplasm.